Botanix Pharmaceuticals Ltd (ASX: BOT) - ETF Exposure
- Current share price for BOT : $0.023
Botanix Pharmaceuticals Limited (BOT) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a dermatology company headquartered in Philadelphia and Phoenix (US). The company has received FDA approval for its lead product, Sofdra, for the treatment of primary axillary hyperhidrosis. Sofdra is the first and only new chemical entity approved by the FDA for this condition, offering a novel solution that combines safety and effectiveness for patients who previously lacked treatment options for this socially challenging medical disorder.
BOT General Information +
| ASX Code | BOT |
| Website | N/A |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 62 |
| BOT Share Price | $0.023 |
| Day High | $0.024 |
| Day Low | $0.022 |
| Last Close | $0.023 |
| BOT Share Price Movement | - ( No change ) |
Prices as at 16:40, 10 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Already own an Australian ETF? You may already have meaningful exposure to BOT
Botanix Pharmaceuticals Ltd (BOT) is held across 2 ETFs spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when BOT moves, funds like DACE that hold it can move with it.
For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to BOT , while the average exposure across all 2 ETFs that hold it is around 0% .
Top ETF holdings
Last updated: ETF data and holdings as at 10 August 2026
Own BOT directly or through an ETF?
How does holding Botanix Pharmaceuticals Ltd (BOT) shares directly compare to ETFs that include it?
|
BOT Direct
|
DACE
ASX |
|
|---|---|---|
| Holdings | 1 company | 470 holdings |
| BOT Weight | 100% | 0% |
| Diversification | Single Stock | Broad |
| Annual Cost | Brokerage only | 0.28% p.a. |
| Approx. Yield | - | 2.93% |
| Star Ratings | - |  |
Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not BOT's direct yield. Annual cost uses each ETF's MER.
BOT Exposure on $10,000 investment
How a $10,000 investment in Botanix Pharmaceuticals Ltd (BOT) one week ago compares with ETFs that hold it.
| Security | Investment type | Current price | 7-day price movement | Dollar change | Value today |
|---|---|---|---|---|---|
| Botanix Pharmaceuticals Ltd (BOT) | Direct share | $0.023 | 9.52% | +$952 | $10,952 |
| Dimensional Australian Core Equity (Managed Fund) (DACE) | Equity - Australia Strategy | $19.500 | 3.83% | +$383 | $10,383 |
Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.
Botanix Pharmaceuticals Ltd (BOT) ETFs
2 ETFs hold Botanix Pharmaceuticals Ltd (BOT).
| ETF | BOT Weight | MER | Yield |
|---|---|---|---|
| Dimensional Australian Core Equity (Managed Fund) (DACE) | 0% | 0.28% | 2.93% |
Botanix Pharmaceuticals Ltd (BOT) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Botanix Pharmaceuticals Ltd (BOT) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Botanix Pharmaceuticals Ltd (BOT) price-sensitive announcements
BOT - Botanix Quarterly Activities Report and Appendix 4C Q4 FY26
Botanix Pharmaceuticals Ltd reported significant developments in its Quarterly Activities
Botanix Pharmaceuticals Ltd (BOT)
27 Jul 2026 | 9:12 AM
27 Jul 2026 | 9:12 AM
BOT - Notice of Allowance for US patent on Sofdra drug substance
Botanix Pharmaceuticals Ltd has received a Notice of Allowance from the United States Pate
Botanix Pharmaceuticals Ltd (BOT)
13 Jul 2026 | 9:13 AM
13 Jul 2026 | 9:13 AM
BOT - Intention to Grant a European patent on Sofdra applicator
Botanix Pharmaceuticals Ltd, a dermatology company based in Philadelphia and Phoenix, anno
Botanix Pharmaceuticals Ltd (BOT)
7 Jul 2026 | 9:14 AM
7 Jul 2026 | 9:14 AM
BOT - Botanix Quarterly Activities Report and Appendix 4C Q3 FY26
In the third quarter of FY26, Botanix Pharmaceuticals Ltd reported notable developments in
Botanix Pharmaceuticals Ltd (BOT)
29 Apr 2026 | 8:50 AM
29 Apr 2026 | 8:50 AM
Botanix Pharmaceuticals Ltd (BOT) Recent ASX Announcements
BOT Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2027F | C2 | -$1.20 | -58.90% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2026F | C2 | -$2.80 | -40.20% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$86.40 | -$4.70 | 408.70% | 0.00 | 0.00 | 0.00% | 0.0% |
BOT Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | 2025 A | 2026 F | 2027 F | ||
| Botanix Pharmaceuticals Ltd (BOT) | $63M | 4.0870 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Clarity Pharmaceuticals Ltd (CU6) | $1,004M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,880M | -0.7857 | 0.2462 | 0.9655 | 97.6364 | 78.3448 | 39.8596 | 0.00% | 0.00% | 0.00% |
BOT Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Stewart James Washer | Non-Executive Director | 21 Feb 2019 |
| Dr H. William Bosch | Non-Executive Director | 1 Jul 2016 |
| Mr Daniel Sharp | Non-Executive Director | 22 Mar 2022 |
| Dr Patricia Walker | Non-Executive Director | 25 Aug 2025 |
| Mr Vincent (Vince) Ippolito | President, Executive Chairman, Executive Director | 18 Jul 2019 |
Botanix Pharmaceuticals Ltd (BOT) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 10 Apr 2026 | BOSCH, H. William | Issued | Direct Shares | 1,666,667 | $0.060 | $100,000.020 |
| 10 Apr 2026 | SHARP, Daniel | Issued | Indirect Shares | 833,333 | $0.060 | $49,999.980 |
| 10 Apr 2026 | IPPOLITO, Vince | Issued | Indirect Shares | 1,666,667 | $0.060 | $100,000.020 |
See all changes in directors' interest & trades for Botanix Pharmaceuticals Ltd (BOT) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
BOT Management
| Name | Position |
|---|---|
| Howie McKibbon | Chief Executive Officer |
| Mr Graeme Morissey | Chief Financial Officer, Australia |
| Mr Chris Lesovitz | Chief Financial Officer, United States of America |
| Andrew Bickley | Company Secretary |
BOT Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Botanix Pharmaceuticals Ltd (BOT). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 161,925,059 (8.29%) | Insignia Financial Ltd |
| 102,100,000 (5.21%) | Copia Investment Partners Ltd |
BOT Calendar of Events
| Date | Event |
|---|---|
| 02 March 2027 | Report (Interim) |
| 01 March 2027 | Report (Interim) |
| 26 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
